Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV/AIDS
Pharma
Gilead aims to shake up HIV PrEP market with long-acting launch
The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.
Zoey Becker
Aug 9, 2024 11:42am
Gilead’s twice-yearly PrEP drug shows 100% efficacy
Jun 20, 2024 11:45am
'Greedy' GSK is under fire from the AIDS Healthcare Foundation
Mar 18, 2024 12:23pm
GSK's long-acting HIV med beats daily pills in some patients
Feb 21, 2024 2:00am
Florida's drug importation authorization draws industry backlash
Jan 6, 2024 4:38pm
Gilead outlines impact of $100M push to tackle HIV epidemic
Aug 23, 2023 8:35am
